JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from an underweight rating to a neutral rating in a report issued on Tuesday, November 12th, Briefing.com Automated Import reports. They currently have $8.00 price objective on the stock.
Other equities analysts also recently issued reports about the stock. Cowen set a $9.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research note on Wednesday, August 7th. Wolfe Research began coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, July 19th. They set a peer perform rating and a $9.00 price objective on the stock. BMO Capital Markets dropped their price objective on shares of Teva Pharmaceutical Industries from $11.00 to $9.00 and set a market perform rating on the stock in a research note on Friday, August 9th. Wells Fargo & Co dropped their price objective on shares of Teva Pharmaceutical Industries from $17.00 to $8.00 and set a market perform rating on the stock in a research note on Monday, September 30th. Finally, Royal Bank of Canada reissued a hold rating and set a $10.00 target price on shares of Teva Pharmaceutical Industries in a research report on Thursday, August 8th. Five equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries currently has an average rating of Hold and a consensus price target of $10.83.
Shares of NYSE TEVA traded down $0.02 during mid-day trading on Tuesday, hitting $10.23. 13,005,577 shares of the company’s stock traded hands, compared to its average volume of 22,159,482. The company’s 50-day moving average is $8.27 and its two-hundred day moving average is $8.56. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56. The company has a market capitalization of $11.19 billion, a P/E ratio of 4.56, a PEG ratio of 1.10 and a beta of 1.73. Teva Pharmaceutical Industries has a 1 year low of $6.07 and a 1 year high of $22.29.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, November 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by ($0.02). The business had revenue of $4.26 billion for the quarter, compared to analysts’ expectations of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. Equities analysts anticipate that Teva Pharmaceutical Industries will post 2.26 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. AdvisorNet Financial Inc grew its position in shares of Teva Pharmaceutical Industries by 71.3% in the third quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after purchasing an additional 1,525 shares during the period. First Interstate Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $28,000. Motco acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $28,000. Lindbrook Capital LLC grew its position in shares of Teva Pharmaceutical Industries by 76.6% in the third quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock valued at $31,000 after purchasing an additional 1,935 shares during the period. Finally, Pacer Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $32,000. 57.81% of the stock is owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: The four types of profit margin
Receive News & Ratings for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.